Mr. Daniel Tassé is a Chief Executive Officer & Executive Director at DBV Technologies SA and an Independent Non-Executive Director at REGENXBIO, Inc.
He is on the Board of Directors at DBV Technologies SA, REGENXBIO, Inc., BioQ Pharma, Inc. and Roundtable On Critical Care Policy. Mr. Tassé was previously employed as an Independent Director by HLS Therapeutics, Inc., a Chairman & Chief Executive Officer by Alcresta Therapeutics, Inc., a Senior Independent Director by Indivior PLC, a Member-Health Section Governing Board by Biotechnology Industry Organization, a Chairman, President & Chief Executive Officer by Ikaria, Inc., a GM-Pharmaceuticals & Technologies Business Unit by Baxter International, Inc., a Vice President & Regional Director-Australasia by GlaxoSmithKline Plc, a Member by Healthcare Leadership Council, and a Chief Financial Officer by NRG Energy Ltd.
He also served on the board at Bellerophon Therapeutics, Inc. and Pharmaceutical Research & Manufacturers of America.
He received his undergraduate degree from the University of Montréal.